The in vitro antiviral effects of black elder
The antiviral activities of black elder berries and flowers were the subject of some investigations in the literatures. Elderberries inhibited the HIV isolates in CD4-I cell lines and peripheral blood lymphocytes (Sahpira-Nahor et al. 1995). Incubation of HIV strains with elderberry extract significantly reduced the infectivity of HIV strains. The antiviral effects of elderberries extract were confirmed against several human strains of type A (H3N2, H1N1, H3N2, H1N1) and influenza virus type B (Zakay-Rones et al. 1995). Elderberry extract inhibited the Human influenza A (H1N1) with IC50 of 252 ± 34 μg/mL (Roschek et al. 2009), the propagation of human pathogenic influenza viruses in cats (Krawitz et al. 2011), and immunodeficiency virus (FIV) (Uncini Manganelli et al. 2005). In other study, elderberries had antiviral activity against influenza A, influenza B, HIV, Herpes simplex-1 viruses, and pathogenic chicken coronavirus (Barak et al. 2001; Morag et al. 1997; Chen et al. 2014). Administration of elderberries with olive leaf extract significantly reduced the viral load from 17,000 to 4000 in HIV positive woman (Konlee 1998). Elderberry extract inhibited the viral hemagglutinin for several strains of influenza viruses in cell culture media. Elderberry extract inhibited the hemagglutinin by binding to the virus and inhibit its attachment to glycol-conjugate receptors on the erythrocytes. Elderberry extract inhibited the replication of human and animal influenza viruses. Hemagglutinin mediates the attachment of virus to salic acid residues in glycol-conjugate receptors on host cells membranes. Elderberry extract blocked the viral salidase of influenza virus (Zakay-Rones et al. 1995).
In addition to antiviral activity of elder berries extract, the antiviral activity of elder flowers were confirmed. Elder flowers and leaves methanol extract had antiviral activity against dengue virus serotype-2 (400 μg/mL) (Castillo-Maldonado et al. 2017). A yellow lyophilized powder (SHS-174) hot infusion extract of ground, air-dried elder flowers, Hypericum perforatum aerial parts, and Saponaria oficinalis (100 g; 70 g; 40 g) had anti-viral activity against influenza and herpes simplex virus type 1 (Serkedjieva et al. 1990).
The antiviral activities of elder berries and elder flowers are related to flavonoid contents. The antiviral effects of pure flavonoids were confirmed against herpes simplex virus type 1, Para-influenza, influenza, and respiratory syncytial virus (Mahmood et al. 1993; Nagai et al. 1992).
Cyanidin 3-glucoside and cyanidin 3-sambubioside as the main anthocyanins of elder exhibited the antiviral effects. Flavonoids (5,7,30,40-tetra-O-methylquercetin and 5,7-dihy-droxy-4-oxo-2-(3,4,5-trihydroxyphenyl)chroman-3-yl-3,4,5-tri hydroxyl cyclo hexane carboxylate) are attached to H1N1 virions. The IC50 for 5,7,30,40-tetra-O-methylquercetin and dihydromyricetin were 0.36 and 8.7 μM against H1N1 infections and were comparable with oseltamivir (Tamiflu; 0.32 μM) and amantadine (27 μM) (Roschek et al. 2009). During the spread of Influenza viral infections, the secondary infections by bacteria can lead to severe pneumonia. Elderberry extracts (standard to minimum concentration of 3.2% anthocyanin) decreased the populations of Streptococcus pyogenes (groups C, G) and Branhamella catarrhalis more than 70% (Krawitz et al. 2011). The results of experimental studies confirmed the antiviral and antibacterial activities of elder flowers and elderberries against viral and bacterial respiratory infections, which are related to their flavonoid contents.
Clinical trials on efficacy of black elder in viral infections
In 400 BCE, elder tree is regarded as a medicine for chest. Elderberry extract was a prophylactic treatment for influenza like diseases and there is one report of animal study for treatment of influenza like symptoms in a colony of chimpanzees (Burge et al. 1999).
Commercial products from elder berries extracts are standardized on the base of flavonoids, flavonols and flavones and the major studies were performed on standard elderberries extracts.
There is four properly randomized clinical trials and statistically good scientific evidence of elder efficacy against influenza and influenza like diseases (Ulbricht et al. 2014). Forty infected patients (5–50 years old) with at least three symptoms of flu including “fever higher than 38 °C, myalgia, nasal discharge, and cough” were included in a double blind clinical study. The efficacy of standardized elder berries extract was evaluated on duration of influenza in these patients in comparison with placebo groups. The patients were recommended to use 2–4 teaspoons of syrups containing standardized elder berries extract or placebo for 3 days. The clinical symptoms of headache, fever, rhinitis, pharyngitis, malaise, cough, fatigue, and myalgia were recorded in patients of two groups over a period of 6 days and finally the feeling of improvement or complete cure were recorded. The presence of anti-bodies to influenza A and B, Respiratory syncytial virus (RSV) and adenoviruses were evaluated in two groups of patients. The results of experimental evaluations exhibited that the elderberry berries extract dose dependently inhibited the replication of influenza viruses. At the baseline, the patients complained of headache, fever, myalgia, malaise, fatigue, and rhinitis patients and rarely cough. The fever’s persistence was 4 and 6 days in elderberry extract and placebo groups, respectively. The average days of fever were 2.36 and 3.33 in elderberry extract and placebo groups, respectively. After 3 days of treatment, the clinical symptoms of flu were decreased in 73.3% and 33.3% of elderberry extract and placebo groups. After 2 days, the clinical symptoms were completely cured in 40% and 16.7% of patients from elderberry and placebo groups. The corresponding complete cure reached to 86.7% and 33.4%, after 3 days of treatments, respectively. After 5 days of treatment with placebo, 41.7% of patients were completely cured. The averages duration of flu were 2.7 and 4 days in elderberry extract and placebo groups, respectively. Therefore, treatment of patients (n = 15) with elderberry extract for 3 days improved the clinical symptoms of flu in 93.3% and 91.7% of patients after 2 and 6 days. 90% of patients were completely improved in elderberry extract after 2 days of intervention, but the complete cure was happen in placebo group after 6 days. Elderberry extract enhanced the immune response in patients, so, the hemagglutinin antibody titers for influenza B increased in elderberry group higher than that of placebo group. The treatments were tolerated and no adverse effects were recorded in patients, who received 4 teaspoons of elderberry extract syrup, daily for 3 days (Zakay-Rones et al. 1995).
In second multicenter randomized placebo controlled trial, the efficacy and safety of standardized elderberry extract was evaluated in patients (16–54 years old) with influenza A and B infections (n = 30), in comparison with placebo group (n = 30). The patients of this study had fever higher than 38 °C with at least one clinical symptom of influenza. The patients of each group received 15 mL of elderberry or placebo syrups, four times a day for 5 continuous days. For evaluating the efficacy of treatment, the influenza symptoms (aches, pains, degree and frequency of coughing, mucus discharge, and the quality of sleep), Visual Analogue Scales (VAS), and overall well-being scores were recorded before and after treatment. At the baseline, there was no significant difference between two groups in regard of demographic status, clinical symptoms, VAS scores and the average duration of clinical symptoms. The majority of patients (90%) were improved in elderberry groups after 3–4 days (3.1 ± 1.3) of treatment, while the corresponding improvement was 7–8 days (7.1 ± 2.5) for placebo group (p < 0.001). The use of ancillary therapies was significantly less in the elderberry group compared with placebo group. The elderberry syrup is effective against influenza A virus, more than influenza B type, without any adverse effects (Zakay-Rones et al. 2004). As the results of clinical study showed a significant reduction (3–4 days) was observed for duration of flu in elderberry syrup in comparison with placebo group.
In other double-blind, placebo-controlled study, the efficacy of elderberry extract (175 mg extract) in the form of lozenges was compared with placebo on 64 patients (16–60 years old) with flu like symptoms. The patients were recommended daily to use four lozenges for 2 days. The self‐assessment and the improvement on clinical symptoms of fever, headache, muscle aches, cough, mucus discharge from the respiratory tract, and nasal congestion on the VAS scores were evaluated four times a day during 2‐days of treatment. At the base line, 46.9% and 28.1% of patients in elderberry and placebo groups had fever (37.3–38.8 °C). After 2 days consumption of elderberry lozenges, the means of VAS score for fever significantly reduced from 2.67 ± 1.8 to 0.47 ± 0.64 (p < 0.0001). All patients had the headache at the beginning of study. The VAS scores for headache significantly reduced from 4.47 ± 2.14 to 1.53 ± 1.41 and 0.28 ± 0.63 after 24 and 48 h. The patients with no and mild headache were 78% and 22%, respectively. In placebo group, the VAS scores for headache increased from 3.78 ± 1.66 to 5.25 ± 1.34 over 48 h. 96.9% and 93.8% of the patients had muscle aches in elderberry and placebo groups, respectively. In elderberry group, 87% of patients were free of pain after 48 h (2.87 ± 2.13 to 0.16 ± 0.45) of treatment, while the VAS scores for placebo group increased from 2.13 ± 2.1 to 3.47 ± 1.50 after 48 h. The prevalence of nasal congestions was 100% and 87.5% in elderberry and placebo groups. After 24 and 48 h consumption of elderberry lozenges, the VAS score for nasal congestion significantly reduced from 4.03 ± 2.1 to 1.47 ± 1.14 and 0.56 ± 0.62, respectively. The Vas score for nasal congestion significantly increased from 3.3 ± 1.71 to 4.26 ± 1.81 in placebo group (p < 0.05). The nasal mucus discharges were prevalent in only 50% and 34.3% of patients in elderberry and placebo groups, respectively. After 24 h of treatment with elderberry extract, VAS score exhibited insignificant improvement (p = 0.26) in nasal mucus discharge, while after 48 of treatment with elderberry lozenges, a significant reduction (p = 0.0019) in VAS score from 1.49 ± 1.61 to 0.5 ± 0.52 for nasal mucus discharge was observed. Only one patient in placebo group (6%) had an improvement in nasal mucus discharge. After 48 h of treatment with elderberry, cough relieved in 31% of patients, and 37% of patients had an improvement in cough with VAS score about one. The VAS score for cough increased from 2.19 ± 1.47 to 3.69 ± 1.25 in placebo group. No adverse effects related to elderberry or placebo were reported during the study (Kong 2009). Elderberry lozenges significantly improved fever; headache, muscle aches and nasal congestion during 24 h of treatment, while the cough and mucus discharge improved during 48 h of treatment.
The preventive effects of 300 mg standard elderberry extract (n = 158) in the form of capsule were the subject of double blind placebo (n = 154) controlled clinical trial including 312 passengers of economy class, and its effects on respiratory and mental health were evaluated. Jackson scores were used to evaluate the daily cold duration, cold episode and cold clinical symptoms. The volunteers completed the questionnaires regarding upper respiratory systems, and quality of life before and after travel. The volunteers took two capsules of elderberries (600 mg) or placebo, 10 days before the travel. Then, the treatments were continued by three capsules (900 mg) from one day before travel until 5 days after arriving at destination. The percentage of taken capsules against total administered capsules was used as compliance of study. At the base line, the prevalence of cold episode were insignificant (p = 0.4) and were 17 and 12 in placebo and elderberry groups, respectively. Travelling increased the prevalence of respiratory symptoms in two groups, but the consumption of elderberry extract improved the physical health of volunteers during the clinical study, while showed a decline in physical health of placebo group. The volunteers in placebo group had significant long cold episode (p = 0.05). Elderberries extract significantly reduced the cold duration (4.75 vs. 6.88 days) and cold severity (21 vs. 34) in treated passengers. Elderberry capsules had no significant effect on mental health of participants. No adverse effects were reported for standard elderberry extract during the study (Tiralongo et al. 2016).
The results of four clinical studies were the subject of a meta-analysis (n = 180), which administration of elderberry extract (n = 89) in comparison with control group (n = 91) significantly reduced the clinical respiratory symptoms in patients with influenza, and common cold and the efficacy of elderberry extract against influenza viral infections was higher than that of common cold. Elderberry extract had no overall effect on flu vaccination and the effects of elderberry extract on upper respiratory symptoms of patients with and without flu vaccination were the same. No adverse or sedative effects were reported for elderberry extract during the study, and one complaint for taste of elderberry syrup was reported (Roschek et al. 2009).
The clinical studies (Table 1) confirmed the efficacy of standard elderberry extract in reduction of cold and influenza duration and improvement of their clinical symptoms. Although, German commission E approved the application of elder flowers in treatment of cold and flu, but there is no clinical study for elder flower in treatment of flu, cold or viral respiratory infections.
Table 1 The clinical studies on elderberries extract in treatment of flu like symptoms Mechanisms of action for elder in treatment of viral respiratory infection
Different mechanisms may be responsible for efficacy of elder in management of flu and common cold (Fig. 2).
Hemagglutinin antigens as glycoprotein molecules allow the virus to attach to cellular sialic acid on host cell membrane and fuse to it. The dispersion of virus from infected cells is caused by neuraminidase antigens and break down the cellular sialic acids. Elderberries lectins (SAα2, 6Gals, and particularly Neu5Acα2, 6Gal) bind to sialic acids of host cell membrane and prevent the influenza virus hemagglutinin’s attachment to host cells. Furthermore, elderberry‘s flavonoids attach to hemagglutinin of influenza virus and prevent the viral attachment to host cell receptors (Zakay-Rones et al. 1995). The denaturalization of hemagglutinin spikes of influenza by elder extracts is associated with viral inactivation to pierce and enter the cells and replicate (Janeway et al. 2001).
The other involved mechanism, responsible for antiviral activity of elderberry in treatment of flu and cold is its immune-modulatory effects. The immune-modulatory effects of elder berries are related to anthocyanin content. The immune-modulatory effects of elderberry extracts are associated with cytokines production (cyanidin-3-glucoside and cyanidin-3-sambubioside), phagocytes activation and its immigration to inflamed tissues (Janeway et al. 2001). Elderberry extract increased the influenza viral antibody in comparison with placebo group. Incubation of blood derived monocytes with elderberry extract significantly increased the production of IL-1β, TNF-α, IL-6, IL-8, and TNF-α (Barak et al. 2001). A significant increase in inflammatory cytokine of IFN-γ was observed after administration of elder in insulin deficiency diabetic and normal rats (Badescu et al. 2015). Furthermore, it is reported that the strong immune modulatory effects of elder are related to pectic polysaccharides (Ho 2017).
Administration of elder improved the clinical symptoms of flu and common cold. Three strains of influenza (A, B, C) can be attributed to influenza. Flu infects the entire respiratory system and the onset of symptoms is sudden within a few hours. Fever higher than 101 °F, headache, general aches; and pains are the characteristic symptoms of flu. Cough, chest congestion, sore throat, stuffy nose, fatigue, weakness, and extreme exhaustion are prevalent among patients (Fendrick et al. 2003). The antioxidant effects of elder extracts are responsible for their efficacy in reducing the pain, and fever. The polyphenols (Stoilova et al. 2007; Viapiana and Wesolowski 2017), and anthocyanins in elders (da Silva et al. 2019) are strongly responsible for the antioxidant activities. Elder berries are used as expectorant and mild anti-inflammatory agents in treatment of upper respiratory ailments (Blumenthal et al. 2000). The anti-inflammatory effects of anthocyanins in elder were comparable with acetylsalicylic acid (Wang et al. 1999). A reduction in mucus secretion was observed in presence of elder in laboratory studies (Ueno et al. 1997). Elder may reduce the swelling of mucus membranes and nasal congestion (Ulbricht et al. 2014). Therefore, elderberry extracts by different mechanisms reduced the aches, pain and fever during the outbreak of influenza.